Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postdissection thoracoabdominal aortic aneurysm presenting with narrow true lumen: Outcomes after fenestrated and branched endovascular repair from the international multicenter NArrow-true-lumen DIssection Registry (NADIR) study group.

Journal of vascular surgery·2026
Same author

Multimodal Endovascular Treatment of Post-Dissection Thoracoabdominal Aneurysm Using Adjunctive Advanced Endovascular Techniques Combined to Branched Repair: Case Report.

Reports (MDPI)·2026
Same author

Scalable control techniques for automated configuration of programmable photonic circuits.

Optics letters·2026
Same author

Sequential monitoring and control of a silicon photonic coherent beam adder and analyzer.

Scientific reports·2026
Same author

Inter-Center Radiation Variability in CO<sub>2</sub>-Guided EVAR: Lessons From the Zero Iodine Contrast Multicenter Prospective Study.

Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists·2026
Same author

Countless ways to save LSA: modern techniques and challenges.

The Journal of cardiovascular surgery·2026

Related Experiment Video

Updated: May 22, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Catheter-Based Renal Denervation in Acute Type B Aortic Dissection to Optimize Long-Term Pressure Control.

Giovanni Francesco Baresi1, Andrea Melloni1, Stefano Bonardelli1

  • 1Division of Vascular Surgery, Department of Experimental and Clinical Sciences, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy.

JACC. Case Reports
|May 21, 2026
PubMed
Summary

Renal denervation (RDN) shows promise as a treatment for refractory hypertension in acute type B aortic dissection (TBAD). This first-in-human study demonstrated successful blood pressure control with RDN as an adjunctive therapy.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Nephrology
Keywords:
RDNTBADaortic dissectionkidney malperfusionrefractory hypertensionrenal denervation

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

Related Experiment Videos

Last Updated: May 22, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

Background:

  • Refractory hypertension (RH) is a significant complication of type B aortic dissection (TBAD), impacting both acute and chronic phases.
  • Optimal blood pressure management is crucial for reducing aortic-related adverse events, yet many patients do not reach therapeutic goals.
  • Renal denervation (RDN) is established for chronic RH, but its use in acute TBAD is unexplored.